Bone Fractures with Sodium-Glucose Co-transporter-2 Inhibitors: How Real is the Risk?

Drug Safety

Volumn 40, Issue 2, 2017, Pages 115-119

  Mannucci, Edoardo ^a,b   Monami, Matteo ^b  

^a UNIVERSITY OF FLORENCE   (Italy)

^b CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; PARATHYROID HORMONE; SODIUM GLUCOSE COTRANSPORTER 2; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; 1,25-DIHYDROXYVITAMIN D; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; CANAGLIFLOZIN; GLUCOSIDE; VITAMIN D;

BONE DENSITY; BONE METABOLISM; DRUG MECHANISM; DRUG USE; FRACTURE; HUMAN; NONHUMAN; PARATHYROID HORMONE BLOOD LEVEL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; RISK; VITAMIN BLOOD LEVEL; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; CHEMICALLY INDUCED; DRUG EFFECTS; DRUG LABELING; FOOD AND DRUG ADMINISTRATION; UNITED STATES;

ANIMALS; BENZHYDRYL COMPOUNDS; BONE DENSITY; CANAGLIFLOZIN; DRUG LABELING; FRACTURES, BONE; GLUCOSIDES; HUMANS; HYPOGLYCEMIC AGENTS; PARATHYROID HORMONE; RISK; SODIUM-GLUCOSE TRANSPORTER 2; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; VITAMIN D;

EID: 84994421929     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.1007/s40264-016-0470-5     Document Type: Review

References (18)

1. US Food and Drug Administration. Safety alert on canagliflozin, issued on Oct 10, 2015. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm461876.htm. Accessed 29 July 2016.
2. Watts NB, Bilezikian JP, Usiskin K, et al. Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2016;101:157–66.
3. Bilezikian JP, Watts NB, Usiskin K, et al. Evaluation of bone mineral density and bone biomarkers in patients with type 2 diabetes treated with canagliflozin. J Clin Endocrinol Metab. 2016;101:44–51.
4. US Food and Drug Administration. Medical review for canagliflozin. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204042Orig1s000MedR.pdf. Accessed 29 July 2016.
5. Ljunggren Ö, Bolinder J, Johansson L, et al. Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin. Diabetes Obes Metab. 2012;14:990–9.
6. Harper C, Pattinson AL, Fernando HA, et al. Effects of obesity treatments on bone mineral density, bone turnover and fracture risk in adults with overweight or obesity. Horm Mol Biol Clin Investig. 2016. [Epub ahead of print].
7. Taylor SI, Blau JE, Rother KI. Possible adverse effects of SGLT2 inhibitors on bone. Lancet Diabetes Endocrinol. 2015;3:8–10.
8. Weir MR, Kline I, Xie J, et al. Effect of canagliflozin on serum electrolytes in patients with type 2 diabetes in relation to estimated glomerular filtration rate (eGFR). Curr Med Res Opin. 2014;30:1759–68.
9. US Food and Drug Administration. Medical review for dapagliflozin. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/202293Orig1s000MedR.pdf. Accessed 29 July 2016.
10. Kohan DE, Fioretto P, Tang W, List JF. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int. 2014;85:962–71.
11. US Food and Drug Administration. Medical review for empagliflozin. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204629Orig1s000MedR.pdf. Accessed 29 July 2016.
12. Zinman B, Wanner C, Lachin JM, et al. EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–28.
13. Alba M, Xie J, Fung A, Desai M. The effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on mineral metabolism and bone in patients with type 2 diabetes mellitus. Curr Med Res Opin. 2016;32:1375–85.
14. Wu JH, Foote C, Blomster J, et al. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2016;4:411–9.
15. Starup-Linde J, Frost M, Vestergaard P, Abrahamsen B. Epidemiology of fractures in diabetes. Calcif Tissue Int. 2016. [Epub ahead of print].
16. Kahn SE, Haffner SM, Heise MA, ADOPT Study Group, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355:2427–43.
17. Monami M, Cresci B, Colombini A, et al. Bone fractures and hypoglycemic treatment in type 2 diabetic patients: a case–control study. Diabetes Care. 2008;31:199–203.
18. Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events (DECLARE-TIMI58). Clinicaltrials.gov trial register: study number NCT01730534. https://clinicaltrials.gov/ct2/show/NCT01730534?term=declare+dapagliflozin&rank=1. Accessed 27 July 2016.